enGene Holdings is a clinical-stage biotechnology company that develops genetic medicines delivered directly to the body's mucosal tissues. Its primary product is an immunotherapy drug designed to treat a specific type of bladder cancer that has not responded to standard treatments. I have synthesized my analysis of its core fundamentals, live market action, and peer metrics to provide a comprehensive thesis. What specific areas can I detail for you?
